Sevelamer Tablets

Therapeutic Indication

Hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis

Prevention of renal osteodystrophy and bone mineral disorders

Reduction of vascular calcification and cardiovascular risk

+91 85919 78885

Sevelamer

Tablet

Sevelamer binds dietary phosphate in the gastrointestinal tract, forming insoluble complexes that are excreted in feces. This reduces phosphate absorption, lowering serum phosphate levels. Unlike calcium-based binders, Sevelamer does not increase calcium load, reducing risk of vascular calcification.

Speciality	Nephrology \| Dialysis \| Bone Health
Tags	CKD \| Hyperphosphatemia \| Phosphate Binder
Strength	400 mg 800 mg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Sevelamer tablets work by binding to dietary phosphate in the digestive tract to lower phosphate levels in the blood.

Pharmacokinetics

Absorption: Not systemically absorbed
Distribution: Acts locally in GI tract
Metabolism: Not metabolized
Elimination: Excreted unchanged in feces

Side Effects

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain

Contraindication

Hypophosphatemia
Bowel obstruction
Hypersensitivity to Sevelamer or excipients

Interaction

May reduce absorption of fat-soluble vitamins (A, D, E, K)
Can interfere with absorption of certain drugs (e.g., ciprofloxacin, levothyroxine)

Warning and Precautions

Monitor serum phosphate and calcium regularly
Supplement fat-soluble vitamins if deficiency risk
Use caution in patients with swallowing disorders or severe GI motility issues

Dosage

As directed by the Physician.

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.